Singapore, Dec. 19 -- China and US based HarbourBioMed has announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.

Under the terms of the agreement, Harbour BioMedwill collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery programmes. In return, HarbourBioMed could receive payments totaling$90 million, as well as development and commercial milestones of up to $1.035 billion, along with tiered royalties should Bristol Myers Squibb elect to advance all potential programs.

Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented, "This collaboration leverages our...